[1] ZhAO D, LIU J, WANG M, ZHANG X, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203-212.
[2] BARQUERA S, PEDROZA-TOBIAS A, MEDINA C, et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Arch Med Res. 2015;46(5):328-338.
[3] KATZIR I, ADLER M, KARIN O, et al. Senescent cells and the incidence of age-related diseases. Aging Cell. 2021;20(3):e13314.
[4] HOPKINS PN. Molecular biology of atherosclerosis. Physiol Rev. 2013; 93(3):1317-1542.
[5] ROSS R, AGIUS L. The process of atherogenesis--cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 1992;35 Suppl 2:S34-S40.
[6] GEOVANINI GR, LIBBY P. Atherosclerosis and inflammation: overview and updates. Clin Sci (Lond). 2018;132(12):1243-1252.
[7] ZHU Y, XIAN X, WANG Z, et al. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018; 8(3):80.
[8] WOLF D, LEY K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124(2):315-327.
[9] BÄCK M, YURDAGUL A JR, TABAS I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389-406.
[10] ZHU D, WANG H, ZhANG J, et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol. 2015;87:138-147.
[11] GIMBRONE MA JR, GARCÍA-CARDEÑA G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016;118(4):620-636.
[12] XU S, ILYAS I, LITTLE PJ, et al. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021;73(3):924-967.
[13] BOSTRÖM P, WU J, JEDRYCHOWSKI MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-468.
[14] Askari H, Rajani SF, Poorebrahim M, et al. A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: An introductory review. Pharmacol Res. 2018;129:44-55.
[15] PERAKAKIS N, TRIANTAFYLLOU GA, FERNÁNDEZ-REAL JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324-337.
[16] WANG J, ZHAO YT, ZHANG L, et al. Irisin Improves Myocardial Performance and Attenuates Insulin Resistance in Spontaneous Mutation (Leprdb ) Mice. Front Pharmacol. 2020;11:769.
[17] Gouveia MC, Vella JP, Cafeo FR, et al. Association between irisin and major chronic diseases: a review. Eur Rev Med Pharmacol Sci. 2016;20(19):4072-4077.
[18] Zhang Y, Song H, Zhang Y, et al. Irisin Inhibits Atherosclerosis by Promoting Endothelial Proliferation Through microRNA126-5p. J Am Heart Assoc. 2016;5(9):e004031.
[19] Zhang X, Hu C, Wu HM, et al. Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target. Acta Pharmacol Sin. 2021;42(9):1390-1400.
[20] Byun K, Lee S. The Potential Role of Irisin in Vascular Function and Atherosclerosis: A Review. Int J Mol Sci. 2020;21(19):7184.
[21] 何青松,刘大男,谭娟.鸢尾素对高脂饮食诱导ApoE~(-/-)小鼠动脉粥样硬化形成的影响及其机制[J].山东医药,2020,60(22):39-43.
[22] 何青松,刘大男,谭娟.冠心病患者血清鸢尾素水平变化观察[J].山东医药,2020,60(6):69-71.
[23] 谭娟,刘大男,何青松,等.鸢尾素对载脂蛋白E基因敲除小鼠动脉粥样硬化的影响[J].中国动脉硬化杂志,2017,25(8):773-777.
[24] Lu J, Xiang G, Liu M, et al. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice. Atherosclerosis. 2015;243(2):438-448.
[25] Zang YH, Chen D, Zhou B, et al. FNDC5 inhibits foam cell formation and monocyte adhesion in vascular smooth muscle cells via suppressing NFκB-mediated NLRP3 upregulation. Vascul Pharmacol. 2019;121:106579.
[26] Zheng G, Li H, Zhang T, et al. Irisin protects macrophages from oxidized low density lipoprotein-induced apoptosis by inhibiting the endoplasmic reticulum stress pathway. Saudi J Biol Sci. 2018;25(5): 849-857.
[27] 覃铮,刘大男,肖金翠,等.FNDC5过表达慢病毒载体的构建及稳定转染THP-1细胞系[J].重庆医科大学学报,2020,45(2):212-216.
[28] 王向,韦朝俊,王尧,等.构建过表达FNDC5慢病毒载体抑制平滑肌细胞的增殖与迁移[J].中国组织工程研究,2021,25(35):5670-5675.
[29] ZHANG Y, MU Q, ZHOU Z, et al. Protective Effect of Irisin on Atherosclerosis via Suppressing Oxidized Low Density Lipoprotein Induced Vascular Inflammation and Endothelial Dysfunction. PLoS One. 2016;11(6):e0158038.
[30] DUAN H, ZHANG Q, LIU J, et al. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis. Pharmacol Res. 2021;168:105599.
[31] PAONE S, BAXTER AA, HULETT MD, et al. Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell Mol Life Sci. 2019;76(6):1093-1106.
[32] TAWAKOL A, ABOHASHEM S, ZUREIGAT H. Imaging Apoptosis in Atherosclerosis: From Cell Death, A Ray of Light. J Am Coll Cardiol. 2020;76(16):1875-1877.
[33] Li R, Mittelstein D, Fang K, et al. Angiopoeitin-2 modulates Survivin expression in OxLDL-induced endothelial cell apoptosis. Biochem Biophys Res Commun. 2012;417(1):619-622.
[34] CChiang CY, Ligunas GD, Chin WC, et al. Efficient Nonviral Stable Transgenesis Mediated by Retroviral Integrase. Mol Ther Methods Clin Dev. 2020;17:1061-1070.
[35] Kuroda H, Kutner RH, Bazan NG, et al. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods. 2009;157(2):113-121.
[36] Buchholz CJ, Friedel T, Büning H. Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery. Trends Biotechnol. 2015;33(12):777-790.
[37] Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346-358.
[38] Di Pasquale E, Latronico MV, Jotti GS, et al. Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function. Gene Ther. 2012;19(6): 642-648.
[39] Mai S, Grugni G, Mele C, et al. Irisin levels in genetic and essential obesity: clues for a potential dual role. Sci Rep. 2020;10(1):1020.
[40] Zhang J, Valverde P, Zhu X, et al. Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism. Bone Res. 2017;5:16056.
[41] Mazur-Bialy AI, Pocheć E, Zarawski M. Anti-Inflammatory Properties of Irisin, Mediator of Physical Activity, Are Connected with TLR4/MyD88 Signaling Pathway Activation. Int J Mol Sci. 2017; 18(4):701.
[42] Mazur-Bialy AI, Kozlowska K, Pochec E, et al. Myokine irisin-induced protection against oxidative stress in vitro. Involvement of heme oxygenase-1 and antioxidazing enzymes superoxide dismutase-2 and glutathione peroxidase. J Physiol Pharmacol. 2018;69(1):117-125.
[43] Winn RK, Harlan JM. The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost. 2005;3(8): 1815-1824.
|